MedAdvisor Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

MedAdvisor şirketinin toplam hissedar öz sermayesi A$56.4M ve toplam borcu A$17.6M olup, bu da borç-öz sermaye oranını 31.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla A$100.2M ve A$43.9M dir.

Anahtar bilgiler

31.29%

Borç/özkaynak oranı

AU$17.63m

Borç

Faiz karşılama oranı	n/a
Nakit	AU$12.40m
Eşitlik	AU$56.37m
Toplam yükümlülükler	AU$43.88m
Toplam varlıklar	AU$100.24m

Son finansal sağlık güncellemeleri

Recent updates

Benign Growth For MedAdvisor Limited (ASX:MDR) Underpins Stock's 35% Plummet

Mar 20

The Market Doesn't Like What It Sees From MedAdvisor Limited's (ASX:MDR) Revenues Yet As Shares Tumble 27%

Feb 03

MedAdvisor Limited (ASX:MDR) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 07

Lacklustre Performance Is Driving MedAdvisor Limited's (ASX:MDR) Low P/S

Oct 23

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Jun 26

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Apr 24

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Mar 20

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Dec 15

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Apr 20

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

Jun 29

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Nov 09

Is MedAdvisor (ASX:MDR) A Risky Investment?

Oct 11

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Mar 08

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

Feb 10

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

Jan 18

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

Dec 22

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Dec 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MDR 'nin kısa vadeli varlıkları ( A$29.6M ) kısa vadeli yükümlülüklerini ( A$23.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: MDR şirketinin kısa vadeli varlıkları ( A$29.6M ) uzun vadeli yükümlülüklerini ( A$20.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MDR 'nin net borç/öz sermaye oranı ( 9.3% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: MDR şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 31.3% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MDR son raporlanan serbest nakit akışına göre 11 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: MDR serbest nakit akışı tahminlerine göre 12 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/20 02:32
Gün Sonu Hisse Fiyatı	2025/05/20 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

MedAdvisor Limited 8 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Anubhav Saxena	Bell Potter
Thomas Wakim	Bell Potter
Elyse Shapiro	Canaccord Genuity

MedAdvisor Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

Is MedAdvisor (ASX:MDR) A Risky Investment?

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Recent updates

MedAdvisor Limited has completed a Follow-on Equity Offering in the amount of AUD 2.668 million.

Consensus EPS estimates fall by 38%

An undisclosed buyer signed a non-binding letter of intent to acquire ANZ business division from MedAdvisor Limited (ASX:MDR) for AUD 42.35 million.

New major risk - Share price stability

New minor risk - Share price stability

Consensus EPS estimates have been downgraded.

MedAdvisor Limited has completed a Follow-on Equity Offering in the amount of AUD 5 million.

Benign Growth For MedAdvisor Limited (ASX:MDR) Underpins Stock's 35% Plummet

Consensus revenue estimates decrease by 11%, EPS upgraded

First half 2025 earnings released: EPS: AU$0.003 (vs AU$0.013 in 1H 2024)

New minor risk - Profitability

New minor risk - Financial position

The Market Doesn't Like What It Sees From MedAdvisor Limited's (ASX:MDR) Revenues Yet As Shares Tumble 27%

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 100%

Consensus revenue estimates fall by 12%

Price target decreased by 19% to AU$0.46

MedAdvisor Limited (ASX:MDR) Held Back By Insufficient Growth Even After Shares Climb 26%

New minor risk - Share price stability

New minor risk - Market cap size

Lacklustre Performance Is Driving MedAdvisor Limited's (ASX:MDR) Low P/S

MedAdvisor Limited Announces the Resignation of Anthony Tassone as Non-Executive Director

MedAdvisor Limited, Annual General Meeting, Nov 14, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

MedAdvisor Limited Announces Board Resignations

Forecast breakeven date pushed back to 2025

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Price target increased by 13% to AU$0.51

Consensus EPS estimates upgraded to AU$0.0033 loss

Forecast breakeven date moved forward to 2025

Consensus EPS estimates fall by 11%, revenue upgraded

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Forecast breakeven date pushed back to 2026

New minor risk - Profitability

Now 24% overvalued after recent price rise

Consensus estimates of losses per share improve by 33%

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Non-Executive Director recently bought AU$1.2m worth of stock

MedAdvisor Limited, Annual General Meeting, Nov 28, 2023

Consensus estimates of losses per share improve by 32%

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 50%

MedAdvisor Limited Announces Board Changes

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Consensus EPS estimates fall by 80%, revenue upgraded

First half 2023 earnings released: EPS: AU$0.009 (vs AU$0.02 loss in 1H 2022)

Price target increased to AU$0.40

MedAdvisor Limited Provides Revenue Guidance for the First Half of the Fiscal Year 2023

MedAdvisor Limited Appoints Kevin Hutchinson as Director

Less than half of directors are independent

MedAdvisor Limited to Report Q1, 2023 Results on Oct 28, 2022

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited, Annual General Meeting, Nov 30, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

MedAdvisor Limited (ASX:MDR) entered a binding agreement to acquire GuildLink Pty Ltd from Guild Group Holdings Limited for AUD 8 million.

MedAdvisor Limited Announces Executive Changes

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

MedAdvisor Limited Announces Change of Managing Director

Price target decreased to AU$0.40

No longer forecast to breakeven

Less than half of directors are independent

MedAdvisor Limited Announces Retirement of Robert Read as CEO

Consensus forecasts updated

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited to Report First Half, 2022 Results on Feb 25, 2022

MedAdvisor Limited Appoints Raeann Grossman to the Board as A Non-Executive Director

Independent Non-Executive Director Peter Bennetto has left the company

Non-Executive Director recently sold AU$2.5m worth of stock